Centessa Pharmaceuticals plc
CNTA
$29.07
$0.561.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 15.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 15.00M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 15.00M | -- | -- |
| SG&A Expenses | 12.23M | 11.91M | 12.33M | 13.71M | 12.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.79M | 54.65M | 45.78M | 74.58M | 46.41M |
| Operating Income | -53.79M | -54.65M | -30.78M | -74.58M | -46.41M |
| Income Before Tax | -54.73M | -49.57M | -24.74M | -110.28M | -41.96M |
| Income Tax Expenses | 166.00K | 778.00K | 1.40M | 1.05M | 608.00K |
| Earnings from Continuing Operations | -54.89M | -50.34M | -26.14M | -111.33M | -42.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.89M | -50.34M | -26.14M | -111.33M | -42.57M |
| EBIT | -53.79M | -54.65M | -30.78M | -74.58M | -46.41M |
| EBITDA | -53.55M | -54.43M | -30.56M | -74.49M | -46.17M |
| EPS Basic | -0.41 | -0.38 | -0.20 | -0.84 | -0.37 |
| Normalized Basic EPS | -0.25 | -0.23 | -0.12 | -0.36 | -0.23 |
| EPS Diluted | -0.41 | -0.38 | -0.20 | -0.84 | -0.37 |
| Normalized Diluted EPS | -0.25 | -0.23 | -0.12 | -0.36 | -0.23 |
| Average Basic Shares Outstanding | 134.16M | 133.68M | 133.03M | 132.05M | 116.25M |
| Average Diluted Shares Outstanding | 134.16M | 133.68M | 133.03M | 132.05M | 116.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |